Pharma major Lupin announced the launch of Tadalafil Tablets USP 20mg, having received an approval from the United States Food and Drug Administration (FDA) earlier.
Lupin’s Tadalafil Tablets USP 20mg is the generic equivalent of Eli Lilly’s Adcirca Tablets 20mg. It is indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise ability.
Tadalafil Tablets, 20mg (RLD: Adcirca) had annual sales of approximately US$474.3 million in the US (IQVIA MAT December 2018).
Shares of the company declined Rs 11.2, or 1.35%, to settle at Rs 819.20. The total volume of shares traded was 91,843 at the BSE (Monday).